(Q46225984)

English

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy

scientific article published on 27 November 2008

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

(3aS)-palonosetron

1 reference

based on heuristic

inferred from title

3

object named as

Hyman Muss

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

author name string

Steven M Grunberg

1

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Matthew Dugan

2

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Marie Wood

4

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Susan Burdette-Radoux

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Tracey Weisberg

6

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Marisa Siebel

7

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

publication date

27 November 2008

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Supportive Care in Cancer

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

17

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

5

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

589-594

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

https://scigraph.springernature.com/pub.10.1007/s00520-008-0535-9

0 references

Current position of 5HT3 antagonists and the additional value of NK1 antagonists; a new class of antiemetics

1 reference

https://api.crossref.org/works/10.1007%2FS00520-008-0535-9

21 January 2018

On the receiving end. V: Patient perceptions of the side effects of cancer chemotherapy in 1993.

1 reference

https://api.crossref.org/works/10.1007%2FS00520-008-0535-9

21 January 2018

Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of chemotherapy-induced nausea and vomiting in Mexico: healthcare provider predictions versus observed

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of chemotherapy-induced nausea and vomiting in Taiwan: physicians' and nurses' estimation vs. patients' reported outcomes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Aprepitant when added to a standard antiemetic regimen consisting of ondansetron and dexamethasone does not affect vinorelbine pharmacokinetics in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 St

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

ASHP Therapeutic Guidelines on the Pharmacologic Management of Nausea and Vomiting in Adult and Pediatric Patients Receiving Chemotherapy or Radiation Therapy or Undergoing Surgery

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Frequency and predictors of prescription-related issues after hospital discharge

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized double-blind comparison of single high-dose ondansetron and multiple standard-dose ondansetron in chemotherapy-naive pediatric oncology patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Optimal two-stage designs for phase II clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

One-month adherence in children with new-onset epilepsy: white-coat compliance does not occur.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chemotherapy-induced nausea and vomiting: incidence and impact on patient quality of life at community oncology settings

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Incidence of chemotherapy-induced nausea and emesis after modern antiemetics

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adherence to initial adjuvant anastrozole therapy among women with early-stage breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Medication adherence in patients who have heart failure: a review of the literature

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with breast cancer after moderately emetogenic chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evidence-based recommendations for the use of antiemetics in radiotherapy.

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

1 reference

https://pubmed.ncbi.nlm.nih.gov/19037667

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00520-008-0535-9

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 December 2017

http://europepmc.org/abstract/MED/19037667

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46225984&oldid=2100478287"